American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

Journal of Oncology Practice

Volumn 6, Issue 6, 2010, Pages 317-320

  Rizzo, J Douglas ^a   Brouwers, Melissa ^a   Hurley, Patricia ^a   Seidenfeld, Jerome ^a   Somerfield, Mark R ^a   Temin, Sarah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CORTICOSTEROID; DOXORUBICIN; HEMOGLOBIN; IRON; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ANEMIA; BONE MARROW SUPPRESSION; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG USE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MEDICAL SOCIETY; NEOPLASM; PRACTICE GUIDELINE; QUALITY OF LIFE; SHORT SURVEY; THROMBOEMBOLISM; TREATMENT INDICATION;

EID: 79952380217     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2010.000132     Document Type: Short Survey

References (4)

1. American Society of Clinical Oncology-American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. http://www.asco.org/guidelines/esa
2. American Society of Hematology/American Society of Clinical Oncology: Clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood http://www.hematology.org/guidelines/esa/
3. Amgen Inc: Aranesp (darbepoetin alfa) for injection. http://www. accessdata.fda.gov/drugsatfda-docs/label/2010/103951s5197lbl.pdf
4. Amgen Inc: Procrit (epoetin alfa) for injection. http://www.accessdata. fda.gov/drugsatfda-docs/label/2010/103234s5199lbl.pdf